Surgical outcomes after pancreatic surgery in patients with a germline CDKN2A/p16 pathogenic variant under surveillance

Br J Surg. 2024 Jan 3;111(1):znad430. doi: 10.1093/bjs/znad430.

Authors

Anke M Onnekink¹, Nynke Michiels², Derk C F Klatte¹, Lotte Oldenburg³, J Sven D Mieog², Alexander L Vahrmeijer², Jeanin E van Hooft¹, Monique E van Leerdam^{1

4}, Bert A Bonsing²

Affiliations

¹ Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands.
² Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
³ Department of Gastroenterology and Hepatology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
⁴ Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

PMID: 38156443
DOI: 10.1093/bjs/znad430

No abstract available

MeSH terms

Cyclin-Dependent Kinase Inhibitor p16 / genetics
Digestive System Surgical Procedures*
Genetic Predisposition to Disease
Germ-Line Mutation
Humans
Melanoma* / pathology
Pancreatic Neoplasms* / epidemiology
Pancreatic Neoplasms* / genetics
Pancreatic Neoplasms* / surgery
Treatment Outcome

Substances

CDKN2A protein, human
Cyclin-Dependent Kinase Inhibitor p16